Publications
Specialty
Search
Wound Care
05/28/2024
Legacy Medical Consultants is initiating a 120-patient interventional study comparing SOC to Orion TM Amniotic Membrane for the treatment of DFUs. The primary outcome measure is incidence of complete wound closure at 12 weeks. The estimated study completion date is 7/25. clinicaltrials.gov
Wound Care
05/28/2024
PolarityTE announced the company has secured $22.5MM in financing to advance SkinTE Phase III Pivotal Study in DFUs. COVER DFUS II will enroll up to 120 patients at up to 20 clinical sites in the US. The primary endpoint is percent DFUs closed at 12 weeks.
Wound Care
05/28/2024
A review of EMR for 5,040 wounds from outpatient clinics showed that 68% would have been suitable to receive sNPWT instead of tNPWT due to size. Surgical wounds were 45%, PIs were 20%, DFUs were 17%, and the most common locations were LE (52%) and Torso (45%). SAWC Spring 24 Poster
Wound Care
05/28/2024
Kerecis presented data from the ODIN RCT, an EU multicenter trial for UT Grade 2 and 3 DFUs. The 255-patient trial compared FSG to SOC with the primary endpoint percent closure at 16 weeks. Healing in the FSG group was 44% at 16 weeks and 26% in the SOC (P<0.001). SmartTRAK at SAWC Spring 2024
Journal of Clinical Pathways
05/28/2024
Ryan Motte, PharmD, discusses how oncology drug shortages have impacted patients with chronic lymphocytic leukemia.
EMSWorld
05/28/2024
Founder and CEO of Jump Aero is working to make the JA1 Pulse electric Vertical Takeoff and Landing (eVTOL) one-person EMS aircraft capable of getting a paramedic/EMT to a critical patient as soon as possible.
Oncology
05/28/2024
Marina Kremyanskaya, MD, PhD, shares study results from the REVIVE trial in which rusfertide demonstrated improved hematocrit control and decreased the use of phlebotomy among patients with polycythemia vera.
EP Lab Digest
05/28/2024
SAN FRANCISCO -- WearLinq, a leading provider of wearable health monitoring and diagnosis solutions, today announced the acquisition of
First Report Managed Care
05/28/2024
The role of artificial intelligence (AI) is becoming increasingly significant, particularly in enhancing the customer experience for health plan members. Health plan executives have a unique opportunity to leverage AI’s potential, mirroring the significant shifts seen in the digital era's evolution from pre-internet to internet, and subsequently to mobile technology.
Vascular Disease Management, CardioVascular
05/28/2024
The first data from a randomized controlled trial looking into the treatment of arteriovenous fistula (AVF) stenosis was announced today by Dr Tan Chieh Suai from Singapore General Hospital.
First Report Managed Care
05/28/2024
Study examines the effectiveness of the Learning to BREATHE mindfulness-based intervention in improving fatigue and mood challenges in a adolescent population with neuroimmune disease.
Cath Lab Digest, CardioVascular, Journal of Invasive Cardiology
05/28/2024
In the United States there are over 8 million active athletes. Given the rapid expansion of sports cardiology, cardiovascular care teams must understand contemporary care and practice management strategies for all athletes—from the elite to the exercise enthusiast. The ACC Care of the Athletic Heart conference, taking place in Washington, on June 6-8, aims to provide clinicians with guideline-driven, practical, cardiovascular care strategies to improve the care of athlete patients and will showcase the latest data and research from the field.
Veterans Health Today
05/28/2024
Adding resuscitative endovascular balloon occlusion of the aorta (REBOA) to standard care in the emergency department did not improve, and may even have hurt, survival in trauma patients with exsanguinating hemorrhage, according to a UK-based study published in JAMA.
First Report Managed Care
05/28/2024
Recent research found that patients on ocrelizumab and rituximab are at a higher risk of contracting SARS-CoV-2 despite being vaccinated, compared to those on ofatumumab.
Neurology
05/28/2024
Continuous positive airway pressure (CPAP) therapy is safe and effective in patients with obstructive sleep apnea (OSA) syndrome, according to study findings published in the journal Respiratory Physiology & Neurobiology.
Cath Lab Digest, Journal of Invasive Cardiology, CardioVascular
05/28/2024
Plozasiran is an RNA interference drug that targets specific RNA molecules in the body that are responsible for the production of APOC3, a key regulator of triglyceride-rich lipoprotein metabolism. High levels of APOC3, caused by genetics or metabolic factors such as diet, obesity and diabetes, slow down the breakdown of triglycerides and, in turn, can lead to cardiovascular disease.
Psych Congress Network
05/28/2024
In Part 2 of this interview Lenard A. Adler, MD, explains the root causes behind the stimulant medication shortage as well as non-pharmacological strategies clinicians can share with their Adult ADHD patients.
First Report Managed Care
05/28/2024
Following Asembia 2024, an expert emphasizes the critical role of specialty pharmacies in patient care and highlights payers' increasing coverage of high-cost biologics and oncology medications, driven by value-based contracts and real-world effectiveness data.
Oncology
05/28/2024
According to a phase 1b/2 trial, trastuzumab deruxtecan with or without pertuzumab showed promising efficacy among previously untreated patients with HER2-positive metastatic breast cancer, with safety profiles consistent with the known safety profiles of both drugs.
Oncology
05/28/2024
According to a phase 2 trial presented at the 2024 ASCO Annual Meeting, adding stereotactic body radiotherapy to chemotherapy did not prolong progression-free survival for patients with advanced cholangiocarcinoma, however more mature data is needed.